Ovarian cancer symptom awareness and anticipated delayed presentation in a population sample

BMC Cancer

Kate E Brain⁵  Stephanie Smits⁵  Alice E Simon²  Lindsay J Forbes³  Chris Roberts⁴  Iain J Robbé⁷  John Steward⁶  Ceri White⁶  Richard D Neal¹  Jane Hanson⁸ 

[1] North Wales Centre for Primary Care Research, Bangor University, Bangor, UK

[2] CR-UK Health Behaviour Research Centre, University College London, London, UK

[3] Promoting Early Presentation Group, King’s College London, London, UK

[4] Knowledge and Analytical Services, Welsh Government, Cardiff, UK

[5] Cochrane Institute of Primary Care and Public Health, Neuadd Meirionydd, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4YS, UK

[6] Welsh Cancer Intelligence and Surveillance Unit, Cardiff, UK

[7] Faculty of Medicine, Memorial University, Newfoundland, Canada

[8] Cancer National Specialist Advisory Group, Cardiff, UK

关键词: Anticipated delay;    Awareness;    Symptoms;    Ovarian cancer;   

Others  :  858985
DOI  :  10.1186/1471-2407-14-171

 received in 2013-11-14, accepted in 2014-02-25,  发布年份 2014

【 摘 要 】

Background

While ovarian cancer is recognised as having identifiable early symptoms, understanding of the key determinants of symptom awareness and early presentation is limited. A population-based survey of ovarian cancer awareness and anticipated delayed presentation with symptoms was conducted as part of the International Cancer Benchmarking Partnership (ICBP).

Methods

Women aged over 50 years were recruited using random probability sampling (n = 1043). Computer-assisted telephone interviews were used to administer measures including ovarian cancer symptom recognition, anticipated time to presentation with ovarian symptoms, health beliefs (perceived risk, perceived benefits/barriers to early presentation, confidence in symptom detection, ovarian cancer worry), and demographic variables. Logistic regression analysis was used to identify the contribution of independent variables to anticipated presentation (categorised as < 3 weeks or ≥ 3 weeks).

Results

The most well-recognised symptoms of ovarian cancer were post-menopausal bleeding (87.4%), and persistent pelvic (79.0%) and abdominal (85.0%) pain. Symptoms associated with eating difficulties and changes in bladder/bowel habits were recognised by less than half the sample. Lower symptom awareness was significantly associated with older age (p ≤ 0.001), being single (p ≤ 0.001), lower education (p ≤ 0.01), and lack of personal experience of ovarian cancer (p ≤ 0.01). The odds of anticipating a delay in time to presentation of ≥ 3 weeks were significantly increased in women educated to degree level (OR = 2.64, 95% CI 1.61 – 4.33, p ≤ 0.001), women who reported more practical barriers (OR = 1.60, 95% CI 1.34 – 1.91, p ≤ 0.001) and more emotional barriers (OR = 1.21, 95% CI 1.06 – 1.40, p ≤ 0.01), and those less confident in symptom detection (OR = 0.56, 95% CI 0.42 – 0.73, p ≤ 0.001), but not in those who reported lower symptom awareness (OR = 0.99, 95% CI 0.91 – 1.07, p = 0.74).

Conclusions

Many symptoms of ovarian cancer are not well-recognised by women in the general population. Evidence-based interventions are needed not only to improve public awareness but also to overcome the barriers to recognising and acting on ovarian symptoms, if delays in presentation are to be minimised.

【 授权许可】

   
2014 Brain et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Cancer research UK ovarian cancer UK statistics [http://publications.cancerresearchuk.org/downloads/Product/cs_pdf_ovarian_march_2011.pdf webcite]
• [2]Maringe C, Walters S, Butler J, Coleman MP, Hacker N, Hanna L, Mosgaard BJ, Nordin A, Rosen B, Engholm G, Gjerstorff ML, Hatcher J, Johannesen TB, McGahan CE, Meechan D, Middleton R, Tracey E, Turner D, Richards MA, Rachet B, ICBP Module 1 Working Group: Stage at diagnosis and ovarian cancer survival: evidence from the international cancer benchmarking partnership. Gynecol Oncol 2012, 127:75-82.
• [3]Richards MA, Westcombe AM, Love SB, Littlejohns P, Ramirez AJ: Influence of delay on survival in patients with breast cancer: a systematic review. Lancet 1999, 353:1119-1126.
• [4]Wardle J, Waller J, Brunswick N, Jarvis MJ: Awareness of risk factors for cancer among British adults. Public Health 2001, 115:173-174.
• [5]Robb K, Stubbings S, Ramirez A, Macleod U, Austoker J, Waller J, Hiom S, Wardle J: Public awareness of cancer in Britain: a population-based survey of adults. Brit J Cancer 2009, 101:18-123.
• [6]Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, Nur U, Tracey E, Coory M, Hatcher J, McGahan CE, Turner D, Marrett L, Gjerstorff ML, Johannesen TB, Adolfsson J, Lambe M, Lawrence G, Meechan D, Morris EJ, Middleton R, Steward J, Richards MA, ICBP Module 1 Working Group: Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995—2007 (the international cancer benchmarking partnership): an analysis of population-based cancer registry data. Lancet 2011, 377:127-138.
• [7]Bankhead C, Collins C, Stokes-Lampard H, Rose P, Wilson S, Clements A, Mant D, Kehoe S, Austoker J: Identifying symptoms of ovarian cancer: a qualitative and quantitative study. Brit J Obs Gyn 2008, 115:1008-1014.
• [8]Hamilton W, Peters TJ, Bankhead C, Sharp D: Risk of ovarian cancer in women with symptoms in primary care: population based case–control study. BMJ 2009, 339:b2998. doi:10.1136/bmj.b2998
• [9]Goff BA, Mandel L, Muntz HG, Melancon CH: Ovarian carcinoma diagnosis: results of a national ovarian cancer survey. Cancer 2000, 89:2068-2075.
• [10]Smith EM, Anderson B: The effects of symptoms and delay in seeking diagnosis on stage of disease at diagnosis among women with cancers of the ovary. Cancer 1985, 56:2727-2732.
• [11]Department of Health key messages for ovarian cancer for health professionals [http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_110534 webcite]
• [12]National Institute for Health and Clinical Excellence (NICE) guidance: Ovarian Cancer: The Recognition and Initial Management of Ovarian Cancer. Cardiff: National Collaborating Centre for Cancer; 2011.
• [13]Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P: Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 2007, 335:136.
• [14]Cancer Facts & Figures. Atlanta: American Cancer Society; 2011. [http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-029771.pdf webcite]
• [15]Department of Health key messages for ovarian cancer for members of the public [http://www.eveappeal.org.uk/media/42340/km_ovarian.pdf webcite]
• [16]Richards MA: The national awareness and early detection initiative: size of the prize for earlier diagnosis of cancer in England. Brit J Cancer 2009, 101:S125-S129.
• [17]National Audit of Cancer Diagnosis in Primary Care London: Royal College of General Practitioners; 2011. [http://www.rcgp.org.uk/news/2011/november/~/media/Files/News/National_Audit_of_Cancer_Diagnosis_in_Primary-Care.ashx webcite]
• [18]Goff BA, Mandel LS, Drescher CW, Urban N, Gough S, Schurman KM, Patras J, Mahony BS, Andersen MR: Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 2007, 109:221-227.
• [19]Andersen MR, Goff BA, Lowe KA, Scholler N, Bergan L, Dresher CW, Paley P, Urban N: Combining a symptoms index with CA 125 to improve detection of ovarian cancer. Cancer 2008, 113:484-489.
• [20]Andersen MR, Goff BA, Lowe KA, Scholler N, Bergan L, Dresher CW, Paley P, Urban N: Use of a Symptom Index, CA125 and HE4 to predict ovarian cancer. Gynecol Oncol 2010, 116:378-383.
• [21]Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, Lewis S, Davies S, Philpott S, Lopes A, Godfrey K, Oram D, Herod J, Williamson K, Seif MW, Scott I, Mould T, Woolas R, Murdoch J, Dobbs S, Amso NN, Leeson S, Cruickshank D, McGuire A, Campbell S, Fallowfield L, Singh N, Dawnay A, Skates SJ, Parmar M, Jacobs I: Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009, 10:327-340.
• [22]Ramirez AJ, Westcombe AM, Burgess CC, Sutton S, Littlejohns P, Richards MA: Factors predicting delayed presentation of symptomatic breast cancer: a systematic review. Lancet 1999, 353:1127-1131.
• [23]Grunfeld E, Ramirez A, Hunter M, Richards M: Women’s knowledge and beliefs regarding breast cancer. Brit J Cancer 2002, 86:1373-1378.
• [24]Burgess CC, Ramirez A, Richards M, Love S: Who and what influences delayed presentation in breast cancer? Brit J Cancer 1998, 77:1343-1348.
• [25]Macleod U, Mitchell ED, Burgess C, Macdonald S, Ramirez AJ: Risk factors for delayed presentation and referral of symptomatic cancer: evidence for common cancers. Brit J Cancer 2009, 101:92-101.
• [26]Smith LK, Pope C, Botha JL: Patients’ help-seeking experiences and delay in cancer presentation: a qualitative synthesis. Lancet 2005, 366:825-831.
• [27]Brouha XD, Tromp DM, Hordijk GJ, Winnubst JA, de Leeuw JR: Oral and pharyngeal cancer: analysis of patient delay at different tumor stages. Head Neck 2005, 27:939-945.
• [28]Cancer in Wales 1995–2009: a comprehensive report Welsh Cancer Intelligence and Surveillance Unit; 2011. [http://www.wales.nhs.uk/sites3/Documents/242/8%20Gynaecological%20Cancers.pdf webcite]
• [29]Becker MH: The health belief model and sick role behavior. Health Educ Monogr 1974, 2:409-419.
• [30]Bandura A: Self-efficacy: The Exercise of Control. New York: Freeman; 1997.
• [31]Rosenstock IM, Strecher VJ, Becker HM: Social learning theory and the health belief model. Health Educ Q 1988, 15:175-183.
• [32]Hay JL, McCaul KD, Magnan RE: Does worry about breast cancer predict screening behaviors? A meta-analysis of the prospective evidence. Prev Med 2006, 42:401-408.
• [33]Forbes LJL, Simon AE, Warburton F, Boniface D, Brain KE, Dessaix A, Donnelly C, Haynes K, Hvidberg L, Lagerlund M, Lockwood G, Tishelman C, Vedsted P, Vigmostad MN, Ramirez AJ, Wardle J, International Cancer Benchmarking Partnership Module 2 Working Group, International Cancer Benchmarking Partnership Programme Board, International Cancer Benchmarking Partnership Module 2 Academic Reference Group: Differences in cancer awareness and beliefs between Australia, Canada, Denmark, Norway, Sweden and the UK (the international cancer benchmarking partnership): do they contribute to differences in cancer survival? Brit J Cancer 2013, 108:292-300.
• [34]Rizzo L, Brick JM, Park I: A minimally intrusive method for sampling persons in random digit dial surveys. Public Opin Q 2004, 68:267-274.
• [35]Simon AE, Forbes LJL, Boniface D, Warburton F, Brain KE, Dessaix A, Donnelly M, Hayne K, Hvidberg L, Lagerlund M, Peterman L, Tishelman C, Vedsted P, Vigmostad MN, Wardle J, Ramirez AJ, ICBP Module 2 Working Group, ICBP Programme Board and Academic Reference Group: An international measure of awareness and beliefs about cancer: development and testing of the ABC. BMJ Open 2012, 2:e001758. doi:10.1136/bmjopen-2012-001758
• [36]Stubbings S, Robb K, Waller J, Ramirez A, Austoker J, Macleod U, Hiom S, Wardle J: Development of a measurement tool to assess public awareness of cancer. Brit J Cancer 2009, 101:s13-s17.
• [37]Simon AE, Wardle J, Grimmett C, Power E, Corker E, Menon U, Matheson L, Waller J: Ovarian and cervical cancer awareness: development of two validated measurement tools. J Fam Plann Reprod Health Care 2012, 38:167-174.
• [38]Cancer research UK “Be clear on cancer” campaign [http://www.cancerresearchuk.org/cancer-info/spotcancerearly/naedi/beclearoncancer/ovarian/ webcite]
• [39]Tyndel S, Henderson B, Austoker J, Brain K, Bankhead C, Clements A, Watson E: What is the psychological impact of mammographic screening on younger women with a family history of breast cancer? Findings from a prospective cohort study by the PIMMS management group. J Clin Oncol 2007, 25:3823-3830.
• [40]Andersen MR, Drescher CW, Zheng Y, Bowen DJ, Wilson S, Young A, McIntosh M, Mahony BS, Lowe KA, Urban N: Changes in cancer worry associated with participation in ovarian cancer screening. Psycho-Oncol 2007, 16:814-820.
• [41]AAPOR: Standard Definitions: Final Dispositions of Case Codes and Outcome Rates for Surveys. 7th edition. The American Association of Public Opinion Research; 2011. http://www.aapor.org/AM/Template.cfm?Section=Standard_Definitions2&Template=/CM/ContentDisplay.cfm&ContentID=3156 webcite
• [42]Scott SE, Grunfeld EA, Auyeung V: Barriers and triggers to seeking help for potentially malignant oral symptoms: implications for interventions. Amer Assoc Publ Health Dentistry 2009, 69:34-40.
• [43]Low EL, Waller J, Menon U, Jones A, Reid F, Simon AE: Ovarian cancer symptom awareness and anticipated time to help-seeking for symptoms among UK women. J Fam Plann Reprod Health Care 2013, 39:163-171.
• [44]Gollwitzer PM: Goal achievement: the role of intentions. Eur Rev Soc Psychol 1993, 4:141-185.
• [45]Neal RD: Do diagnostic delays in cancer matter? Brit J Cancer 2009, 101:S9-S12.
• [46]Evans J, Ziebland S, McPherson A: Minimizing delays in ovarian cancer diagnosis: an expansion of Anderson’s model of ‘total patient delay’. Fam Prac 2006, 24:48-55.
• [47]Andersen MR, Smith R, Meischke H, Bowen D, Urban N: Breast cancer worry and mammography use by women with and without a family history in a population-based sample. Cancer Epid, Bio Prev 2003, 12:314-320.
• [48]Sheeran P: Intention-behaviour relations: a conceptual and empirical review. Eur Rev Soc Psychol 2002, 12:1-36.
• [49]Andersen RS, Vedsted P, Olesen F, Bro F, Søndergaard J: Patient delay in cancer studies: a discussion of methods and measures. BMC Health Serv Res 2009, 9:189. BioMed Central Full Text
• [50]Simon AE, Waller J, Robb K, Wardle J: Patent delay in presentation of possible cancer symptoms: the contribution of knowledge and attitudes in a population sample from the United Kingdom. Cancer Epid, Bio Prev 2010, 19:2272-2277.
• [51]Quaife S, Forbes L, Ramirez A, Brain KE, Donnelly C, Simon AE, Wardle J: Recognition of cancer warning signs and anticipated delay in help-seeking in a population sample of adults in the UK. Brit J Cancer 2013. 10.1038/bjc.2013.684